Deirdre Y. Gillespie

Chief Executive Officer at IRAD Oncology, Inc.

67 year

Health Technology

Consumer Services

Profile

Deirdre Y.
Gillespie currently works at IRAD Oncology, Inc., as Chief Executive Officer from 2013.
Dr. Gillespie also formerly worked at La Jolla Pharmaceutical Co., as President, Chief Executive Officer & Director from 2011 to 2012, Oxxon Therapeutics, Inc., as President & Chief Executive Officer from 2001 to 2005, Virttu Biologics Ltd., as Chief Executive Officer, Apricus Biosciences, Inc., as Independent Director from 2010 to 2016, Vical, Inc., as Chief Operating Officer from 1998 to 2001, and DuPont Merck Pharmaceutical Co., as Vice President-Marketing from 1991 to 1996.
Dr. Gillespie received her undergraduate degree and doctorate degree from the University of London and Masters Business Admin degree from London Business School.

Deirdre Y. Gillespie active positions

Companies	Position	Start
IRAD Oncology, Inc.	Chief Executive Officer	2012-12-31

All active positions of Deirdre Y. Gillespie

Former positions of Deirdre Y. Gillespie

Companies	Position	End
Apricus Biosciences, Inc. Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA.	Director/Board Member	2016-04-04
LA JOLLA PHARMACEUTICAL COMPANY	Chief Executive Officer	2012-01-18
Oxxon Therapeutics, Inc. Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK.	President	2004-12-31
Vical, Inc. Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.	Chief Operating Officer	2000-12-31
DuPont Merck Pharmaceutical Co. DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million.	Sales & Marketing	1995-12-31

See the detail of Deirdre Y. Gillespie's experience

Training of Deirdre Y. Gillespie

University of London	Doctorate Degree
London Business School	Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Deirdre Y. Gillespie's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	7
Vical, Inc. Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.	Health Technology
La Jolla Pharmaceutical Co. La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA.	Health Technology
Apricus Biosciences, Inc. Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA.	Health Technology
DuPont Merck Pharmaceutical Co. DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million.	Health Technology
Oxxon Therapeutics, Inc. Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK.	Health Technology
IRAD Oncology, Inc.
Virttu Biologics Ltd. Virttu Biologics Ltd. Pharmaceuticals: OtherHealth Technology Virttu Biologics Ltd. operates as a biopharmaceutical company. It develops oncolytic virus therapy for treatment of cancer. The firm's product candidate Seprehvir (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and eliciting an anti-tumor immune response in the patient. The company is headquartered in Glasgow, the United Kingdom.	Health Technology

See company connections